Implementación de una programa para el control del uso de antifúngicos en un hospital general universitario ("Antifungal stewardship")

El consumo inapropiado de antifúngicos ha contribuido en años recientes al incremento global de la resistencia antifúngica y ha jugado un papel importante en los cambios epidemiológicos y en la etiología de las infecciones fúngicas. Además, el sobreuso de antifúngicos conlleva un riesgo de toxicidad asociada a los mismos y un muy significativo aumento en el gasto sanitario. Los programas de control del uso de antifúngicos consisten en intervenciones multidisciplinares, lideradas por especialistas en enfermedades infecciosas, microbiología clínica y farmacia, que establecen redes de cooperación y comunicación con los principales servicios prescriptores, con el fin de optimizar el tratamiento antifúngico y el manejo de las infecciones fúngicas invasivas. Sin embargo, la experiencia en el desarrollo de programas de optimización del uso de antifúngicos es muy limitada, pues la mayoría de los esfuerzos se han centrado en el control de los antibacterianos...

Discovery and validation of serologic biomarkers for the diagnosis and prognosis of invasive candidiasis by computational immunomics

Invasive candidiasis (IC) is an opportunistic systemic mycosis caused by Candida species (commonly Candida albicans) that continues to pose a significant public health problem worldwide. Despite great advances in antifungal therapy and changes in clinical practices, IC remains a major infectious cause of morbidity and mortality in severely immunocompromised or critically ill patients, and further accounts for substantial healthcare costs. Its impact on patient clinical outcome and economic burden could be ameliorated by timely initiation of appropriate antifungal therapy. However, early detection of IC is extremely difficult because of its unspecific clinical signs and symptoms, and the inadequate accuracy and time delay of the currently available diagnostic or risk stratification methods. In consequence, the diagnosis of IC is often attained in advanced stages of infection (leading to delayed therapeutic interventions and ensuing poor clinical outcomes) or, unfortunately, at autopsy. In addition to the difficulties encountered in diagnosing IC at an early stage, the initial therapeutic decision-making process is also hindered by the insufficient accuracy of the currently available tools for predicting clinical outcomes in individual IC patients at presentation. Therefore, it is not surprising that clinicians are generally unable to early detect IC, and identify those IC patients who are most likely to suffer fatal clinical outcomes and may benefit from more personalized therapeutic strategies at presentation. Better diagnostic and prognostic biomarkers for IC are thus needed to improve the clinical management of this life-threatening and costly opportunistic fungal infection...